Keith Tapper
Stock Analyst at BMO Capital
(2.89)
# 1,760
Out of 5,044 analysts
6
Total ratings
66.67%
Success rate
36.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $45 → $16 | $30.96 | -48.32% | 4 | Apr 14, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $4.99 | +0.20% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $22.62 | +37.05% | 1 | Jun 27, 2024 |
Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45 → $16
Current: $30.96
Upside: -48.32%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $4.99
Upside: +0.20%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $22.62
Upside: +37.05%